Project Grant R01CA293572
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$542K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) provides $249,000.00 to The Trustees of the University of Pennsylvania to conduct research on understanding the genetic and epigenetic drivers of glioma tumor evolution and progression. The 3-year project will develop novel single-cell multi-omics technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This data will be used to create a...
The federal Project Grant award R01CA299870, totaling $371,719.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award, effective March 1, 2025 through February 28, 2030, supports research by The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, to investigate the role of the epigenetic modifier NSD2 in regulating the androgen receptor (AR)...
The National Cancer Institute (NCI) awarded a $602,486 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Health Research, Inc., a not-for-profit research organization based in Buffalo, NY. The grant aims to explore the feasibility of targeting retrotransposons, or mobile genetic elements, as a novel approach to treating refractory pediatric cancers, with a primary focus on high-risk neuroblastoma. The project seeks to comprehensively characterize retrotransposon activity...
The federal Project Grant award from the National Cancer Institute (NCI) provides $159,803 over a period of 5 years (9/3/2024 - 8/31/2029) to support the "INTEGRATIVE MULTIOMICS AND CLINICAL LABORATORY TRANSLATION FOR ADVANCED, RARE, AND PEDIATRIC CANCERS" project. The award aims to incorporate emerging genomic, transcriptomic, epigenomic and proteomic technologies to analyze advanced, rare, and pediatric cancers, and translate the results into clinically actionable information through...
This $521,579 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund research by the University of Texas Southwestern Medical Center to characterize the role of the hepatic leukemia factor (HLF) gene in regulating lung metastasis in clear cell renal cell carcinoma (CCRCC). The research aims to use CRISPR screening, gain-of-function and loss-of-function studies, and integrated ChIP-Seq and RNA-Seq analysis to delineate the molecular mechanisms...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the University of Wisconsin-Madison for research to elucidate the molecular mechanisms underlying Wilms Tumor (WT) caused by CTR9 gene mutations and develop better treatments. The $218,089 award, beginning February 1, 2025 and completing by January 31, 2027, will support the engineering of cell lines to examine how the deletion of exon 9 in the CTR9 gene disrupts...
This $700,619 federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to study and control rhythmic nephron formation for kidney replacement tissues. The primary awardee, The Trustees of the University of Pennsylvania, aims to define the spatiotemporal coordination of cell-cell interactions that drive the rhythmic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $483,760.00 to The Trustees of the University of Pennsylvania to conduct research aimed at understanding the role of the DCAF15 protein in acute myeloid leukemia (AML). The key objectives of this 5-year project are to: (a) investigate the biological function of DCAF15 in myeloid development and leukemia in vivo, (b) examine the role of cohesin acetylation in AML pathogenesis,...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $238,890 in funding to Duke University to conduct research focused on understanding the relationship between chromosomal instability, 17p loss, and sensitivity to inhibition of the mitotic regulator NDE1 in metastatic cancers. The research aims to define the link between NDE1 dependence, 17p loss, and chromosomal instability, characterize the role of NDE1 in chromosome segregation, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for research at the Icahn School of Medicine at Mount Sinai to investigate mechanisms of therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. The $441,178 award, with a project period from August 2024 to July 2029, aims to: 1) determine the cellular and developmental dependency of NUP98-NSD1-mediated leukemic initiation, 2) characterize the effects...